Rivastigmine patch
Drugacetylcholine esterase inhibitor
Other names: exelon patch
NCT Number: NCT02413554
Delirium is a common and serious condition and is associated with adverse outcome. The elderly who have cognitive dysfunction are expected to show delirium more frequently. It is most likely that delirium represents a response to impaired cholinergic neurotransmission. Investigators aimed to establish the preventive effect of the cholinesterase inhibitor, rivastigmine patch, on the post-operative delirium limited to femur neck fracture operation in patients at risk of dementia.
Looking for future studies?
Notify Me65 year and older
All sexes
Interventional
Phase 4
Investigators evaluated the delirium prevention effect of rivastigmine patch in patients with femur neck fracture and cognitive impairment. Investigators measured the frequency and severity of post-operation delirium in the patch applied and non-applied subjects.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
acetylcholine esterase inhibitor
Other names: exelon patch
Time frame: up to 7th days
investigators evaluated the delirium frequency in rivastigmine applied participants comparing with non-applied participants.
Time frame: up to 7th days
to compare the severity of delirium in rivastigmine patch applied participants with non-applied
Chung-Ang University Hospital
Other
Rivastigmine Patch Effect on the Post-operative Delirium Limited to Femur Neck Fracture Operation in Patients at Risk of Dementia.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02548975
Confusion, Delirium
View Trial DetailsNCT06963112
Anxiety, Anxiety Disorders
Guangxi, China
View Trial DetailsNCT07151716
Confusion, Delirium
Beijing, Beijing Municipality, China
View Trial DetailsNCT03317067
Aberrant Motor Behavior in Dementia, Agitation
Clermont-Ferrand, France
View Trial Details